[ad_1]
SmarterAnalyst
Emergency Use List for Johnson & Johnson’s Single Dose COVID-19 Vaccine by WHO
Johnson & Johnson’s single-dose COVID-19 vaccine, which was developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), has been given an Emergency Use List (EUL) by the World Health Organization. health (WHO). The world’s largest healthcare company designed the vaccine to prevent COVID-19 in people 18 and older. Data published as part of the Phase 3 ENSEMBLE study shows that Johnson & Johnson’s single-injection COVID-19 vaccine (JNJ) has a favorable tolerability profile. In addition, the study confirmed that the reduction in symptomatic illness of COVID-19 in people who received the vaccine compared to people who received the placebo was 67%. In addition, the data confirmed the vaccine’s 85% efficacy in preventing serious illness in all regions studied and demonstrated that the vaccine protects against hospitalization and death from COVID-19 in countries with different variants, starting 28 days after vaccination. Last December, Johnson & Johnson and Gavi, the Vaccine Alliance, agreed in principle in favor of the COVAX facility. The two are likely to enter into an Advance Purchase Agreement (APA) that would provide 500 million doses of the company’s vaccine to COVAX through 2022. (See Johnson & Johnson market analysis on TipRanks) Johnson & Johnson Executive Committee VC Paul Stoffels said: The WHO list of our single injection COVID-19 vaccine confirms our commitment to help stem this pandemic and our unwavering commitment to equitable access. “Achieving this important prerequisite for the distribution of our vaccine through the COVAX facility, co-led by Gavi, is a major step forward in making our vaccine accessible to all,” added Stoffels. In recent months, the company has also received emergency use authorization (EUA) for the vaccine in the United States from the Food and Drug Administration (FDA) and provisional authorization in Canada, as well as an authorization. conditional marketing (CMA) in the European Union. On January 27, JP Morgan analyst Chris Schott raised the share price target to $ 175 (upside potential 9.7%) from $ 157 and reiterated a Hold rating “following the results of the fourth quarter of the company ”. The consensus rating among analysts is a strong buy based on 10 buy versus 1 hold. The analysts’ average price target stands at $ 189.90 and implies upside potential of 19% from current levels. Shares have gained 25.5% over the past year. On top of that, Johnson & Johnson scores a “Perfect 10” on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Altimmune Expands Partnership With Lonza To Support Production Of AdCOVID Inks Cardinal Health $ 1 Billion Accord To Sell Cordis Business Sanofi, Translate Bio Launch Human COVID-19 Vaccine Trial; Stocks Gain 5% Newer Smarter Analyst Articles: Century Casinos Gain 4% on 4Q Profit Win Four Corners Buys Caliber Collision Property for $ 1.9M Charles Schwab’s Feb. The street sees 10% on the rise
[ad_2]
Source link